PharmaBlock Sciences has acquired a GMP compliant manufacturing facility in China from Porton Pharma Solutions Ltd. 

The 1,436,000ft² (approximately 133,400m²) site, located in a State-level chemical industry park in Shangyu, Zhejiang Province, has been operating as a multi-purpose GMP compliant facility since December 2015. Assets include reactors from 300L to 6300L, with more than 180m³ of combined reactor volume. The facility is well equipped to practice a wide range of chemistry synthesis and enabling technologies, and expands PharmaBlock’s manufacturing capacity of building blocks, RSMs, non-GMP and GMP intermediates. 

It has delivered 100+ products from Phase I to commercial, with production over 150 MT since January 2016. Phase II construction will be implemented this year to establish API manufacturing capabilities.

“PharmaBlock’s new Shangyu site is well positioned to respond to customers’ increasing demand for preclinical-, clinical- and commercial- stage manufacturing of intermediates. The acquisition of this site provides additional GMP capacity and is supplement to our existing assets in Shandong Dezhou site.” said Dr. Minmin Yang, chairman of PharmaBlock. “We will initiate the Phase II construction of Shangyu facility within this year to establish API manufacturing capabilities. In this way, PharmaBlock will soon be able to offer customers an integrated supply chain from building blocks, non-GMP intermediates, GMP intermediates to APIs.”